Pfizer's Biggest Shot at Lipitor 2.0

Pfizer's (NYSE: PFE  ) rheumatoid arthritis drug tofacitinib has a new name -- it use to be called tasocitinib -- but the data in the company's second phase 3 trial was the same as the first: a solid win.

The pharma giant didn't release the data -- it's saving it for a medical meeting -- but Pfizer did say the trial showed that the drug was better than placebo in multiple scales used to determine the severity of rheumatoid arthritis.

In the previous trial, 59.8% of patients reported 20% improvement of their symptoms, while the higher dose helped 65.7% of patients to report the same. The results were double the 26.7% of the patients taking placebo that improved their symptoms by 20%.

Tofacitinib should have little problem competing with the megablockbuster rheumatoid arthritis drugs -- Abbott Labs' (NYSE: ABT  ) Humira, Johnson & Johnson (NYSE: JNJ  ) and Merck's (NYSE: MRK  ) Remicade, and Pfizer and Amgen's (Nasdaq: AMGN  ) Enbrel -- because it's taken orally, unlike the others, which have to be injected or infused.

The biggest obstacle to tofacitinib's success isn't what's in front of it, but what's trailing behind. Rigel Pharmaceuticals (Nasdaq: RIGL  ) and Incyte (Nasdaq: INCY  ) are both developing oral rheumatoid arthritis drugs in combination with AstraZeneca and Eli Lilly, respectively.

If the drugs work as well or better than tofacitinib, the head start Pfizer has might not amount to much. However, if they stumble in their respective phase 3 trials, Pfizer will have a major seller on its hands. Sales might not approach Lipitor's $12-billion scale, but billions -- with an "s" -- certainly isn't out of the question.

Pfizer isn't ready to submit a marketing application just yet. Tofacitinib still has four more trials to read out for rheumatoid arthritis, and multiple others in additional inflammatory diseases such as psoriasis and inflammatory bowel disease. Assuming the drug continues the clinical trial success, the results will be worth the wait.

Follow Pfizer as it tries to replace lost sales from Lipitor. Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Pfizer.

Johnson & Johnson and Pfizer are Motley Fool Inside Value selections. Johnson & Johnson is a Motley Fool Income Investor pick. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Abbott Laboratories, and Johnson & Johnson. Motley Fool Alpha owns shares of Abbott Laboratories and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1452929, ~/Articles/ArticleHandler.aspx, 12/22/2014 9:19:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement